Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Biztoc.com - January 7, 2025

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Jefferies upgraded Instil Bio (NASDAQ:TIL), noting that 2024 was a banner year for the PD-(L)1xVEGF class. Summit Therapeutics’ (NASDAQ:SMMT) data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China demonstrated a statis…

Read Full Article
International Analysis

Other Relevant News

First Step

Welcome

By signing up, you declare that you agree to our terms of use and privacy policies.
Opportunities Today

Enjoy

Your Passport to Global Investments

Ivar recommends Swissquote bank for your international investments. By opening your account through the link below and trading 5 lots or more, you will receive $200 to use on Ivar AI and activate your subscription. Take advantage of this exclusive offer available today!

Swissquote

Offer available for you who have not yet opened your account at Swissquote.
Services available globally except for the following countries: Algeria, Belgium, Canada, China, North Korea, USA, France, Hong Kong, Iran, Iraq, Nigeria, Singapore, Syria, Turkey and Zimbabwe.